|
|
|
|
|
|
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
100 Clinical Results associated with Histone H1 x DNA
100 Translational Medicine associated with Histone H1 x DNA
0 Patents (Medical) associated with Histone H1 x DNA